What is HistoGenetics?
HistoGenetics operates at the intersection of advanced molecular diagnostics and clinical transplantation support. The company provides a comprehensive suite of services, including high-resolution HLA typing, whole genome sequencing, and sophisticated genomic analyses. By catering to donor registries, transplant centers, and specialized HLA laboratories, HistoGenetics has established itself as a critical partner in the precision medicine ecosystem. Their commitment to delivering cost-effective, high-throughput sequencing solutions enables healthcare providers and research institutions to improve patient outcomes through data-driven immunogenetic insights.
The firm's operational model is designed to address the rigorous demands of modern clinical environments, where accuracy and turnaround time are paramount. By leveraging cutting-edge sequencing methodologies, HistoGenetics facilitates the complex matching processes required for successful transplantation and pharmacogenomic applications, effectively bridging the gap between raw genetic data and actionable clinical intelligence.
How much funding has HistoGenetics raised?
HistoGenetics has raised a total of $1M across 1 funding round:
Debt
$1M
Debt (2020): $1M with participation from PPP
Key Investors in HistoGenetics
PPP
Public-Private Partnership
What's next for HistoGenetics?
With this recent infusion of capital, HistoGenetics is well-positioned to scale its laboratory operations and expand its footprint in the global precision medicine market. The strategic allocation of these funds will likely focus on enhancing technological infrastructure, potentially accelerating the development of proprietary sequencing platforms and broadening the scope of their diagnostic service offerings. As the demand for personalized healthcare solutions continues to rise, the company is poised to leverage its established expertise to capture additional market share within the immunogenetics sector. Future growth initiatives will likely prioritize the integration of artificial intelligence in genomic data interpretation, further cementing the company's status as a leader in high-complexity diagnostic services.
See full HistoGenetics company page
